Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD)

Current Pharmaceutical Design

Volumn 16, Issue 32, 2010, Pages 3554-3573

  Adcock, Ian M ^a   Marwick, John ^b   Casolari, Paolo ^c   Contoli, Marco ^c   Chung, Kian Fan ^c   Kirkham, Paul ^c   Papi, Alberto ^c   Caramori, Gaetano ^c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Asthma; COPD; Glucocorticoids; GR; HDAC; PI3K

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTISENSE OLIGONUCLEOTIDE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLECALCIFEROL; CORTICOSTEROID; CYTOSOL RECEPTOR; FLUTICASONE; GLUCOCORTICOID RECEPTOR; I KAPPA B; INTERLEUKIN 5 ANTIBODY; JNK 401; KETOLIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MOMETASONE FUROATE; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PREDNISOLONE; PREDNISONE; SALMETEROL; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL SUPPRESSION; ARTICLE; ASTHMA; BONE DENSITY; CATARACT; CHROMATIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CUSHINGOID SYNDROME; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DNA MODIFICATION; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSPNEA; GASTROINTESTINAL ABSORPTION; GENE EXPRESSION; GENE REPRESSION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GROWTH RETARDATION; HEART FAILURE; HUMAN; LOW DRUG DOSE; LUNG BIOPSY; LUNG FUNCTION; METABOLIC DISORDER; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OSTEOPOROSIS; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA STABILITY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN FRAGILITY; TH17 CELL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT OBSTRUCTION;

ADRENAL CORTEX HORMONES; ASTHMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 78650909855     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793797889     Document Type: Article

References (268)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995a; 332: 868-875.
2. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action andresistance. J Allergy Clin Immunol 2006a; 117: 522-43.
3. Savory JG, Hsu B, Laquian IR, et al. Discrimination between NL1-and NL2-mediated nuclear localization of the glucocorticoid recep-tor. Mol Cell Biol 1999; 19: 1025-37.
4. Weigel NL, Moore NL. Steroid receptor phosphorylation: a keymodulator of multiple receptor functions. Mol Endocrinol 2007;21: 2311-9.
5. Freedman ND, Yamamoto KR. Importin 7 and importin al-pha/importin beta are nuclear import receptors for the glucocorti-coid receptor. Mol Biol Cell 2004; 15: 2276-86.
6. Liu J, DeFranco DB. Protracted nuclear export of glucocorticoidreceptor limits its turnover and does not require the exportin1/CRM1-directed nuclear export pathway. Mol Endocrinol 2000;14: 40-51.
7. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroidresistance. Chest 2008a; 134: 394-401.
8. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006b; 203: 7-13.
9. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. Determi-nants of celland gene-specific transcriptional regulation by theglucocorticoid receptor. PLoS Genet 2007; 3: e94.
10. So AY, Cooper SB, Feldman BJ, Manuchehri M, Yamamoto KR.Conservation analysis predicts in vivo occupancy of glucocorticoidreceptor-binding sequences at glucocorticoid-induced genes. Proc Natl Acad Sci USA 2008; 105: 5745-9.
11. De Bosscher K, Van Craenenbroeck K, Meijer OC, Haegeman G.Selective transrepression versus transactivation mechanisms byglucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol 2008; 583: 290-302.
12. Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defec-tive induction of IL-10-secreting regulatory T cells in glucocorti-coid-resistant asthma patients. J Clin Invest 2006; 116: 146-55.
13. Li B, Carey M, Workman JL. The role of chromatin during tran-scription. Cell 2007; 128: 707-19.
14. Roh TY, Cuddapah S, Zhao K. Active chromatin domains aredefined by acetylation islands revealed by genome-wide mapping. Genes Dev 2005; 19: 542-52.
15. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATsand HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138: 1019-31.
16. Clark AR, Martins JR, Tchen CR. Role of dual specificity phospha-tases in biological responses to glucocorticoids. J Biol Chem 2008;283: 25765-9.
17. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective gluco-corticoid receptor agonists (SEGRAs): Novel ligands with an im-proved therapeutic index. Mol Cell Endocrinol 2007; 275: 109-17.
18. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding ofthe glucocorticoid receptor is not essential for survival. Cell 1998;93: 531-41.
19. Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression ofinflammatory responses in the absence of DNA binding by the glu-cocorticoid receptor. EMBO J 2001; 20: 7168-73.
20. Luecke HF, Yamamoto KR. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific tran-scriptional repression. Genes Dev 2005; 19: 1116-1127.
21. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitmentof histone deacetylase 2 inhibits interleukin-1beta-induced histoneH4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20: 6891-903.
22. Nie M, Knox AJ, Pang L. beta2-Adrenoceptor agonists, like gluco-corticoids, repress eotaxin gene transcription by selective inhibitionof histone H4 acetylation. J Immunol 2005; 175: 478-486.
23. Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroidinsensitivity of alveolar macrophages in severe asthma compared tonon-severe asthma. Thorax 2008; 6: 784-790.
24. Meyer S, Temme C, Wahle E. Messenger RNA turnover in eu-karyotes: pathways and enzymes. Crit Rev Biochem Mol Biol 2004; 39: 197-216.
25. Jalonen U, Lahti A, Korhonen R, Kankaanranta H, Moilanen E.Inhibition of tristetraprolin expression by dexamethasone in acti-vated macrophages. Biochem Pharmacol 2005; 69: 733-740.
26. Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. In-flammatory cells and eosinophilic activity in asthmatics investi-gated by bronchoalveolar lavage. The effects of antiasthmatictreatment with budesonide or terbutaline. Am Rev Respir Dis 1990;142: 91-9.
27. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johans-son SA. Effects of treatment on airway inflammation and thicken-ing of basement membrane reticular collagen in asthma. A quanti-tative light and electron microscopic study. Am Rev Respir Dis. 1992; 145: 890-899.
28. Laitinen LA, Laitinen A, Haahtela T. A comparative study of theeffects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosedasthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.
29. Laursen LC, Taudorf E, Borgeskov S, Kobayasi T, Jensen H,Weeke B. Fiberoptic bronchoscopy and bronchial mucosal biopsiesin asthmatics undergoing long-term high-dose budesonide aerosoltreatment. Allergy 1988; 43: 284-8.
30. van Rensen EL, Straathof KC, Veselic-Charvat MA, ZwindermanAH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyper-responsiveness, sputum eosinophils, and exhaled nitric oxide levelsin patients with asthma. Thorax 1999; 54: 403-8.
31. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-termtreatment with low-dose inhaled fluticasone propionate on airwayinflammation and remodeling in mild asthma: a placebo-controlledstudy. Am J Respir Crit Care Med 1997; 155: 1864-71.
32. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999; 54: 289-95.
33. Brieva JL, Danta I, Wanner A. Effect of an inhaled glucocorticos-teroid on airway mucosal blood flow in mild asthma. Am J RespirCrit Care Med 2000; 161: 293-6.
34. Gibson PG, Wong BJ, Hepperle MJ, et al. A research method toinduce and examine a mild exacerbation of asthma by withdrawalof inhaled corticosteroid. Clin Exp Allergy 1992; 22: 525-32.
35. Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ,Bel EH. Lung function and sputum characteristics of patients withsevere asthma during an induced exacerbation by double-blindsteroid withdrawal. Am J Respir Crit Care Med 1999; 160: 93-9.
36. Maneechotesuwan K, Essilfie-Quaye S, Kharitonov SA, AdcockIM, Barnes PJ. Loss of control of asthma following inhaled corti-costeroid withdrawal is associated with increased sputum interleu-kin-8 and neutrophils. Chest 2007; 132: 98-105.
37. Chung KF. Role of inflammation in the hyperreactivity of the air-ways in asthma. Thorax 1986; 41: 657-62.
38. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990; 141: S70-6.
39. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'ByrnePM, Hargreave FE. Long-term effects of budesonide on airway re-sponsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990a; 3: 1122-7.
40. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'ByrnePM, Hargreave FE. Effect of long-term treatment with an inhaledcorticosteroid (budesonide) on airway hyperresponsiveness andclinical asthma in nonsteroid-dependent asthmatics. Am Rev RespirDis 1990b; 142: 832-6.
41. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate ismore closely associated with reduction in airway inflammation thanimprovement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164: 1127-32.
42. Ward C, Pais M, Bish R, et al. Airway inflammation, basementmembrane thickening and bronchial hyperresponsiveness inasthma. Thorax 2002; 57: 309-16.
43. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistantasthma: the need for an integrated approach to define clinical phe-notypes, evaluate risk factors, understand pathophysiology and findnovel therapies. ERS Task Force on Difficult/Therapy-ResistantAsthma. European Respiratory Society. Eur Respir J 1999; 13:1198-208.
44. Wenzel SE, Fahy JV, Irvin CG, Peters SP, Spector S, Szefler SJ.Proceedings of the ATS workshop on refractory asthma: currentunderstanding, recommendations, and unanswered questions.American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341-51.
45. British guideline on the management of asthma. Thorax 2008;63(Suppl 4): 1-121.
46. Global Initiative for Asthma. Global strategy for Asthma Manage-ment and Prevention. NHLBI/WHO Workshop report. 2002. NIHPublication 02-3659. Last update 2010. http://www.ginasthma.com(accessed July 2010).
47. World Health Organization/National Heart, Lung and Blood Insti-tute. Workshop report. Global strategy for asthma management andprevention. Publication no. 95-3659. Bethesda, National Institutesof Health, 1995.
48. National Institutes of Health Expert Panel Report 2: guidelines forthe diagnosis and the management of asthma. NIH publicationnumber 08-4051. Bethesda: NIH/National Heart, Lung and BloodInstitute, 2007.
49. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ,Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22: 478-83.
50. European Network for Understanding Mechanisms of SevereAsthma. The ENFUMOSA cross-sectional European multicentrestudy of the clinical phenotype of chronic severe asthma. EuropeanNetwork for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22: 470-7.
51. Dolan CM, Fraher KE, Bleecker ER, et al. TENOR Study Group.Design and baseline characteristics of the epidemiology and naturalhistory of asthma: Outcomes and Treatment Regimens (TENOR)study: a large cohort of patients with severe or difficult-to-treatasthma. Ann Allergy Asthma Immunol 2004; 92: 32-9.
52. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Ad-cock IM. p38 Mitogen-activated protein kinase-induced glucocorti-coid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-57.
53. Leung DY, Bloom JW. Update on glucocorticoid action and resis-tance. J Allergy Clin Immunol 2003; 111: 3-22; quiz 23.
54. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorti-coid receptor nuclear translocation and altered histone acetylationpatterns in glucocorticoid-resistant patients. J Allergy Clin Immu-nol 2004; 113: 1100-1118.
55. Chanez P, Springall D, Vignola AM, et al. Bronchial mucosalimmunoreactivity of sensory neuropeptides in severe airway dis-eases. Am J Respir Crit Care Med 1998; 158: 985-990.
56. de la Fuente PT, Romagnoli M, Godard P, Bousquet J, Chanez P.Safety of inducing sputum in patients with asthma of varying sever-ity. Am J Respir Crit Care Med 1998; 157: 1127-1130.
57. Vachier I, Chiappara G, Vignola AM, et al. Glucocorticoid recep-tors in bronchial epithelial cells in asthma. Am J Respir Crit CareMed 1998; 158: 963-970.
58. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs ofasthma are correlated with severity: a 1-yr prospective study. EurRespir J 2002; 19: 61-67.
59. Gagliardo R, Chanez P, Vignola AM, et al. Glucocorticoid receptoralpha and beta in glucocorticoid dependent asthma. Am J RespirCrit Care Med 2000; 162: 7-13.
60. Gagliardo R, Chanez P, Mathieu M, et al. Persistent activation ofnuclear factor-kappaB signaling pathway in severe uncontrolledasthma. Am J Respir Crit Care Med 2003; 168: 1190-8.
61. Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerba-tions in severe asthma are associated with enhanced airway closureduring stable episodes. Am J Respir Crit Care Med 2000; 161:1902-6.
62. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Fac-tors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744-8.
63. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Re-fractory eosinophilic airway inflammation in severe asthma: effectof parenteral corticosteroids. Am J Respir Crit Care Med 2004;170: 601-5.
64. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ.Bronchoscopic evaluation of severe asthma. Persistent inflamma-tion associated with high dose glucocorticoids. Am J Respir CritCare Med 1997; 156: 737-43.
65. Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE.Neutrophil-derived matrix metalloproteinase-9 is increased in se-vere asthma and poorly inhibited by glucocorticoids. J Allergy ClinImmunol 2003; 112: 1064-71.
66. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distin-guishing severe asthma phenotypes: role of age at onset and eosi-nophilic inflammation. J Allergy Clin Immunol 2004; 113: 101-8.
67. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that se-vere asthma can be divided pathologically into two inflammatorysubtypes with distinct physiologic and clinical characteristics. Am JRespir Crit Care Med 1999; 160: 1001-8.
68. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool toevaluate small airways in asthma. Eur Respir J 2002; 20: 254-9.
69. Chevalier L. All that wheezes is not asthma. BMQ 1865; 16: 86.
70. Newman KB, Dubester SN. Vocal cord dysfunction: masqueraderof asthma. Sem Respir Crit Care Med 1994; 15: 161-7.
71. Grenier PA, Beigelman-Aubry C, Brillet PY. Nonneoplastic tra-cheal and bronchial stenoses. Thorac Surg Clin 2010; 20: 47-64.
72. Ravenna F, Caramori G, Papi A, et al. An unusual case of congeni-tal short trachea with very long bronchi mimicking bronchialasthma. Thorax 2002; 57: 372-3.
73. Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia andtracheobronchomalacia in children and adults: an in-depth review. Chest 2005; 127: 984-1005.
74. Macchiarini P. Primary tracheal tumours. Lancet Oncol 2006; 7:83-91.
75. Swanson KL, Edell ES. Tracheobronchial foreign bodies. Chest Surg Clin N Am 2001; 11: 861-72.
76. Global Initiative for Chronic Obstructive Lung Disease. GlobalStrategy for the Diagnosis, Management and Prevention of ChronicObstructive Pulmonary Disease. NHLBI/WHO workshop report.Bethesda, National Heart, Lung and Blood Institute, April 2001;NIH Publication No 2701:1-100. Last update 2009.http://www.goldcopd.com (accessed July 4, 2010).
77. Contoli M, Baraldo S, Marku B, et al. Fixed airflow obstructiondue to asthma or chronic obstructive pulmonary disease: 5-year fol-low-up. J Allergy Clin Immunol 2010; 125: 830-7.
78. Regnard J. Cardiac asthma. Rev Mal Respir 2003; 20: S50-4.
79. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergil-losis. Allergy 2005; 60: 1004-13.
80. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome andclonal eosinophilia: point-of-care diagnostic algorithm and treat-ment update. Mayo Clin Proc 2010; 85: 158-64.
81. Thomson CC, Tager AM, Weller PF. Clinical problem-solving.More than your average wheeze. N Engl J Med 2002; 346: 438-42.
82. Rivals A, Rouquet RM, Recco P, Linas MD, Leophonte P, DidierA. A rare cause of asthma exacerbation: systemic anguilluliasis. Rev Mal Respir 2000; 17: 99-102.
83. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthmamanagement and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-78.
84. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistancein asthma. Am J Respir Crit Care Med 1995b; 152: S125-40.
85. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associatedwith persistent airflow obstruction in chronic severe asthma. EurRespir J 2004; 24: 122-8.
86. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterizationof the severe asthma phenotype by the National Heart, Lung, andBlood Institute's Severe Asthma Research Program. J Allergy ClinImmunol 2007; 119: 405-13.
87. Charmandari E, Kino T. Novel causes of generalized glucocorti-coid resistance. Horm Metab Res 2007; 39: 445-50.
88. Lane SJ, Atkinson BA, Swaminathan R, Lee TH. Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma. Am J Respir Crit Care Med 1996; 153: 557-60.
89. Lane SJ, Palmer JB, Skidmore IF, Lee TH. Corticosteroid pharma-cokinetics in asthma. Lancet 1990; 336: 1265.
90. Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleu-kin 4, interleukin 5, and interferon gamma gene expression in ste-roid-resistant asthma. J Exp Med 1995; 181: 33-40.
91. Cohen L, E X, Tarsi J, et al. and the NHLBI Severe Asthma Re-search Program (SARP). Epithelial cell proliferation contributes toairway remodeling in severe asthma. Am J Respir Crit Care Med 2007; 176: 138-145.
92. Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine re-lease in severe asthma. Eur Respir J 2010; 35: 750-756.
93. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insen-sitivity of peripheral blood mononuclear cells in severe asthma. AmJ Respir Crit Care Med 2006; 174: 134-141.
94. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
95. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airwayobstruction in chronic obstructive pulmonary disease. N Engl JMed 2004; 350: 2645-53.
96. Di Stefano A, Caramori G, Ricciardolo FL, Capelli A, Adcock IM,Donner CF. Cellular and molecular mechanisms in chronic obstruc-tive pulmonary disease: an overview. Clin Exp Allergy 2004; 34:1156-67.
97. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticos-teroids vs placebo for preventing COPD exacerbations: a system-atic review and metaregression of randomized controlled trials. Chest 2010; 137: 318-25.
98. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA,Maslen TK. Randomised, double blind, placebo controlled study offluticasone propionate in patients with moderate to severe chronicobstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-303.
99. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K,LeBoff MS. Effects of inhaled glucocorticoids on bone density inpremenopausal women. N Engl J Med 2001; 345: 941-947.
100. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL,Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines,and proteases in induced sputum in chronic obstructive pulmonarydisease. Am J Respir Crit Care Med 1999; 160: 1635-1639.
101. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluti-casone propionate on inflammatory cells in COPD: an ultrastruc-tural examination of endobronchial biopsy tissue. Thorax 2002; 57:799-803.
102. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects ofinhaled and oral glucocorticoids on inflammatory indices in asthmaand COPD. Am J Respir Crit Care Med 1997; 155: 542-8.
103. Lung Health Study Research Group. Effect of inhaled triamci-nolone on the decline in pulmonary function in chronic obstructivepulmonary disease. N Engl J Med 2000; 343: 1902-9.
104. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatmentwith inhaled budesonide in persons with mild chronic obstructivepulmonary disease who continue smoking. European RespiratorySociety Study on Chronic Obstructive Pulmonary Disease. N EnglJ Med 1999; 340: 1948-53.
105. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic ob-structive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
106. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacother-apy on rate of decline of lung function in chronic obstructive pul-monary disease: results from the TORCH study. Am J Respir CritCare Med 2008; 178: 332-338.
107. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and flutica-sone propionate and survival in chronic obstructive pulmonary dis-ease. N Engl J Med 2007; 356: 775-789.
108. bis Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk ofpneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
109. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety ofbudesonide/formoterol in the management of chronic obstructivepulmonary disease. Eur Respir J 2003; 21: 74-81. Erratum in: EurRespir J 2003; 21: 912.
110. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol andfluticasone in the treatment of chronic obstructive pulmonary dis-ease: a randomised controlled trial. Lancet 2003; 361: 449-56.
111. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, vanHerwaarden C. Effect of discontinuation of inhaled corticosteroidsin patients with chronic obstructive pulmonary disease: the COPEstudy. Am J Respir Crit Care Med 2002; 166: 1358-63.
112. Calverley PM, Rennard S, Nelson HS, et al. One-year treatmentwith mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008; 9: 73.
113. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management ofstable chronic obstructive pulmonary disease: a systematic reviewfor a clinical practice guideline. Ann Intern Med 2007; 147: 639-53.
114. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severityand the effect of fluticasone propionate on chronic obstructivepulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
115. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments forchronic obstructive pulmonary disease: a mixed treatment compari-son meta-analysis. Pharmacotherapy 2009; 29:891-905.
116. O'Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawalof inhaled steroids in men with severe irreversible airflow obstruc-tion. Am J Respir Crit Care Med 2001; 164: 365-71.
117. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of flutica-sone propionate from combined salmeterol/fluticasone treatment inpatients with COPD causes immediate and sustained disease dete-rioration: a randomised controlled trial. Thorax 2005; 60: 480-7.
118. Suissa S. Inhaled steroids and mortality in COPD: bias from unac-counted immortal time. Eur Respir J 2004; 23: 391-5.
119. Sin DD, Man SF. Systemic inflammation and mortality in chronicobstructive pulmonary disease. Can J Physiol Pharmacol 2007; 85:141-7.
120. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids onsputum cell counts in stable chronic obstructive pulmonary disease:a systematic review and a meta-analysis. BMC Pulm Med 2005; 5:3.
121. Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by dex-amethasone of cytokine release by alveolar macrophages from pa-tients with chronic obstructive pulmonary disease. Am J Respir CritCare Med 2003; 167: 24-31.
122. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC.The effects of inhaled fluticasone on airway inflammation inchronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165:1592-6.
123. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Oli-venstein R, Hamid Q. Effect of salmeterol/fluticasone propionateon airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-43.
124. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006; 533: 2-14.
125. Korn SH, Thunnissen FB, Wesseling GJ, Arends JW, Wouters EF.Glucocorticoid receptor mRNA levels in bronchial epithelial cellsof patients with COPD: influence of glucocorticoids. Respir Med 1998; 92: 1102-9.
126. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI-3K restores steroid responsiveness in smoking-induced steroid in-sensitivity. Am J Respir Crit Care Med 2009; 179: 542-8.
127. Livingston E, Darroch CE, Chaudhuri R, et al. Glucocorticoidreceptor alpha:beta ratio in blood mononuclear cells is reduced incigarette smokers. J Allergy Clin Immunol 2004; 114: 1475-8.
128. Strickland I, Kisich K, Hauk PJ, et al. High constitutive glucocorti-coid receptor beta in human neutrophils enables them to reducetheir spontaneous rate of cell death in response to corticosteroids. JExp Med 2001; 193: 585-93.
129. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflamma-tory cytokines regulate human glucocorticoid receptor gene expres-sion and lead to the accumulation of the dominant negative betaisoform: a mechanism for the generation of glucocorticoid resis-tance. Proc Natl Acad Sci USA 2001; 98: 6865-70.
130. Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY. In-creased glucocorticoid receptor beta alters steroid response in glu-cocorticoid-insensitive asthma. Am J Respir Crit Care Med 2006;173: 607-16.
131. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38MAPK in COPD. Eur Respir J 2008; 31: 62-9.
132. Kent L, Smyth L, Plumb J, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage in-flammatory gene expression by dexamethasone and the p38 mito-gen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydro-pyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). J Pharmacol Exp Ther 2009; 328: 458-68.
133. Barczyk A, Pierzchala W, Kon OM, Cosio B, Adcock IM, BarnesPJ. Cytokine production by bronchoalveolar lavage T lymphocytesin chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006; 117: 1484-92.
134. Miotto D, Ruggieri MP, Boschetto P, et al. Interleukin-13 and -4expression in the central airways of smokers with chronic bronchi-tis. Eur Respir J 2003; 22: 602-8.
135. Saha S, Mistry V, Siva R, et al. Induced sputum and bronchialmucosal expression of interleukin-13 is not increased in chronicobstructive pulmonary disease. Allergy 2008; 63: 1239-43.
136. Beghé B, Hall IP, Parker SG, et al. Polymorphisms in IL13 path-way genes in asthma and chronic obstructive pulmonary disease. Allergy 201; 65: 474-481.
137. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesisof chronic obstructive pulmonary disease II. Proc Am Thorac Soc 2009; 6: 532-534.
138. Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolonefor preschool children with acute virus-induced wheezing. N Engl JMed 2009; 360: 329-38.
139. Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. NEngl J Med 2009; 360: 339-53.
140. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, LeeTH. Corticosteroid-resistant bronchial asthma is associated with in-creased c-fos expression in monocytes and T lymphocytes. J ClinInvest 1998; 102: 2156-64.
141. Ning W, Li CJ, Kaminski N, et al. Comprehensive gene expressionprofiles reveal pathways related to the pathogenesis of chronic ob-structive pulmonary disease. Proc Natl Acad Sci USA 2004; 101:14895-900.
142. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress andairway inflammation in severe exacerbations of COPD. Thorax 2005; 60: 293-300.
143. Loke TK, Mallett KH, Ratoff J, et al. Systemic glucocorticoidreduces bronchial mucosal activation of activator protein 1 compo-nents in glucocorticoid-sensitive but not glucocorticoid-resistant as-thmatic patients. J Allergy Clin Immunol 2006; 118: 368-75.
144. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic in-flammation. J Exp Med 2005; 202: 1459-63.
145. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 levelin sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999; 14: 309-14.
146. Zhu X, Gadgil AS, Givelber R, et al. Peripheral T cell functionscorrelate with the severity of chronic obstructive pulmonary dis-ease. J Immunol 2009; 182: 3270-7.
147. Isajevs S, Taivans I, Strazda G, et al. Decreased FOXP3 expressionin small airways of smokers with COPD. Eur Respir J 2009; 33:61-67.
148. Plumb J, Smyth LJ, Adams HR, Vestbo J, Bentley A, Singh SD.Increased Tregulatory cells within lymphocyte follicles in moder-ate COPD. Eur Respir J 2009; 34: 89-94.
149. Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa ofstable chronic obstructive pulmonary disease patients. Clin ExpImmunol 2009; 157: 316-24.
150. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediatesteroid-resistant airway inflammation and airway hyperresponsive-ness in mice. J Immunol 2008; 181: 4089-97.
151. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-48.
152. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylaseactivity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-76.
153. Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. Altered epige-netic regulation and increasing severity of bronchial hyperrespon-siveness in atopic asthmatic children. J Allergy Clin Immunol 2009; 124: 1116-8.
154. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ.Theophylline restores histone deacetylase activity and steroid re-sponses in COPD macrophages. J Exp Med 2004; 200: 689-95.
155. Rahman I, Adcock IM. Oxidative stress and redox regulation oflung inflammation in COPD. Eur Respir J 2006; 28: 219-42.
156. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, en-hances cytokine expression, and inhibits glucocorticoid actions inalveolar macrophages. FASEB J 2001; 15: 1110-2.
157. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidativestress reduces histone deacetylase 2 activity and enhances IL-8gene expression: role of tyrosine nitration. Biochem Biophys ResCommun 2004; 315: 240-5.
158. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smokealters chromatin remodeling and induces proinflammatory genes inrat lungs. Am J Respir Cell Mol Biol 2004; 31: 633-42.
159. Marwick JA, Wallis G, Meja K, et al. Oxidative stress modulatestheophylline effects on steroid responsiveness. Biochem BiophysRes Commun 2008; 377: 797-802.
160. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoi-nositide 3-kinase expression in health and disease. Trends Biochem Sci 2009; 34: 115-27.
161. Marwick JA, Caramori G, Casolari P, et al. A role for phosphoi-nositol 3-kinase delta in the impairment of glucocorticoid respon-siveness in patients with chronic obstructive pulmonary disease. JAllergy Clin Immunol 2010; 125: 1146-53.
162. Barnes PJ. Theophylline: new perspectives for an old drug. Am JRespir Crit Care Med 2003a; 167: 813-8.
163. Barnes PJ. Theophylline in chronic obstructive pulmonary disease:new horizons. Proc Am Thorac Soc 2005a; 2: 334-339; discussion340-1.
164. Caramori G, Adcock I. Pharmacology of airway inflammation inasthma and COPD. Pulm Pharmacol Ther 2003; 16: 247-77.
165. Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma.Cochrane Database Syst Rev 2003; 3: CD001281.
166. Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophyl-line plus beclometasone on lung function in smokers with asthma: apilot study. Eur Respir J 2009; 33: 1010-7.
167. Tennant RC, Erin EM, Barnes PJ, Hansel TT. Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients withCOPD: is combination therapy justified? Curr Opin Pharmacol 2003; 3: 270-276.
168. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, BarnesPJ. Treatment effects of low dose theophylline combined with aninhaled corticosteroid in COPD. Chest 2010; 137: 1338-44.
169. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-{delta} with theophylline reverses corticosteroid insensitivityCOPD. Am J Respir Crit Care Med 2010; 182(7): 897-904.
170. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline en-hances the anti-inflammatory effects of steroids during exacerba-tions of chronic obstructive pulmonary disease. Thorax 2009; 64:424-9.
171. Bourbeau J, Johnson M. New and controversial therapies forchronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6: 553-4.
172. Szulakowski P, Crowther AJ, Jiménez LA, et al. The effect ofsmoking on the transcriptional regulation of lung inflammation inpatients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2006; 174: 41-50.
173. Dekker FJ, Haisma HJ. Histone acetyl transferases as emergingdrug targets. Drug Discov Today 2009; 14: 942-8.
174. Bartling TR, Drumm ML. Loss of CFTR results in reduction ofhistone deacetylase 2 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 297: L35-43.
175. Barnes PJ. Targeting histone deacetylase 2 in chronic obstructivepulmonary disease treatment. Expert Opin Ther Targets 2005b; 9:1111-21.
176. Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A.New drugs targeting Th2 lymphocytes in asthma. J Occup Env Med 2008; 3(Suppl 1): S6-S35.
177. Chopra P, Kulkarni O, Gupta S, et al. Pharmacological profile ofAW-814141, a novel, potent, selective and orally active inhibitor ofp38 MAP kinase. Int Immunopharmacol 2010; 10: 467-73.
178. Montalban AG, Boman E, Chang CD, et al. KR-003048, a potent,orally active inhibitor of p38 mitogen-activated protein kinase. EurJ Pharmacol 2010; 632: 93-102.
179. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A random-ized, placebo-controlled study of the effects of the p38 MAPK in-hibitor SB-681323 on blood biomarkers of inflammation in COPDpatients. J Clin Pharmacol 2010; 50: 94-100.
180. Hammaker D, Firestein GS. Go upstream, young man: lessonslearned from the p38 saga. Ann Rheum Dis 2010; 69 (Suppl 1):i77-82.
181. Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunityprotein kinase signalling in inflammation. Nat Rev Drug Discov 2009; 8: 480-99.
182. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticoster-oid and long-acting beta-agonist in one inhaler versus placebo forchronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4: CD003794.
183. Roth M, Johnson PR, Rüdiger JJ, et al. Interaction between gluco-corticoids and beta2 agonists on bronchial airway smooth musclecells through synchronised cellular signalling. Lancet 2002; 360:1293-1299.
184. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoidreceptor nuclear translocation in airway cells after inhaled combi-nation therapy. Am J Respir Crit Care Med 2005; 172: 704-712.
185. Chung KF, Adcock IM. Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma. Treat RespirMed 2004a; 3: 279-89.
186. Sin DD, Man SF. Corticosteroids and adrenoceptor agonists: thecompliments for combination therapy in chronic airways diseases. Eur J Pharmacol 2006; 533: 28-35.
187. Chung KF. Phosphodiesterase inhibitors in airways disease. Eur JPharmacol 2006a; 533: 110-117.
188. Higgs G. Is PDE4 too difficult a drug target? Curr Opin InvestigDrugs 2010; 11: 495-498.
189. Cazzola M, Picciolo S, Matera MG. Roflumilast in chronic obstruc-tive pulmonary disease: evidence from large trials. Expert OpinPharmacother 2010; 11: 441-449.
190. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma andchronic obstructive pulmonary disease. Lancet 2005; 365: 167-175.
191. Barnes PJ. Emerging targets for COPD therapy. Curr Drug TargetsInflamm Allergy 2005c; 4: 675-683.
192. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety ofroflumilast in the treatment of asthma. Ann Allergy Asthma Immu-nol 2006; 96: 679-86.
193. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM,Martinez FJ. M2-124 and M2-125 study groups. Roflumilast insymptomatic chronic obstructive pulmonary disease: two random-ised clinical trials. Lancet 2009; 374: 685-694.
194. Chung KF. Cytokines as targets in chronic obstructive pulmonarydisease. Curr Drug Targets 2006b; 7: 675-81.
195. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. M2-127 andM2-128 study groups. Roflumilast in moderate-to-severe chronicobstructive pulmonary disease treated with long-acting bronchodi-lators: two randomised clinical trials. Lancet 2009; 374: 695-703.
196. Jeffery P. Phosphodiesterase 4-selective inhibition: novel therapyfor the inflammation of COPD. Pulm Pharmacol Ther 2005; 18: 9-17.
197. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction insputum neutrophil and eosinophil numbers by the PDE4 inhibitorroflumilast in patients with COPD. Thorax 2007; 62: 1081-7.
198. Barnes PJ, Chung KF, Page CP. Inflammatory mediators ofasthma: an update. Pharmacol Rev 1998; 50: 515-96.
199. Jampilek J, Dolezal M, Opletalova V, Hartl J. 5-Lipoxygenase,leukotrienes biosynthesis and potential antileukotrienic agents. Curr Med Chem 2006; 13: 117-29.
200. Kalayci O, Birben E, Sackesen C, et al. ALOX5 promoter geno-type, asthma severity and LTC production by eosinophils. Allergy 2006; 61: 97-103.
201. McGill KA, Busse WW. Zileuton. Lancet 1996; 348: 519-24.
202. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prosta-glandins Leukot Essent Fatty Acids 2003; 69: 99-109.
203. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathwaypolymorphisms on response to montelukast in asthma. Am J RespirCrit Care Med 2006; 173: 379-85.
204. Lam BK. Leukotriene C(4) synthase. Prostaglandins Leukot EssentFatty Acids 2003; 69: 111-6.
205. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4)receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 123-34.
206. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE.Cysteinyl-leukotrienes and their receptors in asthma and other in-flammatory diseases: critical update and emerging trends. Med ResRev 2007; 27: 469-527.
207. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cyste-inyl leukotriene 1 receptor in normal human lung and peripheralblood leukocytes. Am J Respir Crit Care Med 2001; 163: 226-33.
208. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr.Roles of cysteinyl leukotrienes in airway inflammation, smoothmuscle function, and remodeling. J Allergy Clin Immunol 2003;111(1 Suppl): S18-34; discussion S34-6.
209. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared toinhaled corticosteroids in the management of recurrent and/orchronic asthma in adults and children. Cochrane Database Syst Rev 2004; 2: CD002314.
210. Ducharme F, Schwartz Z, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.Cochrane Database Syst Rev 2004; CD003133.
211. Gompertz S, Stockley RA. A randomized, placebo-controlled trialof a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122: 289-294.
212. Grönke L, Beeh KM, Cameron R, et al. Effect of the oral leukot-riene B4 receptor antagonist LTB019 on inflammatory sputummarkers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21: 409-17.
213. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancio-glu A. Shortterm effects of montelukast in stable patients withmoderate to severe COPD. Respir Med 2005; 99: 444-50.
214. Rubinstein I, Kumar B, Schriever C. Long-term montelukast ther-apy in moderate to severe COPD--a preliminary observation. Respir Med 2004; 98: 134-8.
215. Chung KF. Anti-IgE monoclonal antibody, omalizumab: a newtreatment for allergic asthma. Expert Opin Pharmacother 2004b; 5:439-46.
216. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; 2: CD003559.
217. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689-2695.
218. Kraft M, Cassell GH, Henson JE, et al. Detection of Mycoplasmapneumoniae in the airways of adults with chronic asthma. Am JRespir Crit Care Med 1998; 158: 998-1001. Erratum in: Am JRespir Crit Care Med 1998; 158: 1692.
219. Chu HW, Kraft M, Krause JE, Rex MD, Martin RJ. Substance Pand its receptor neurokinin 1 expression in asthmatic airways. J Al-lergy Clin Immunol 2000; 106: 713-22.
220. Chu HW, Kraft M, Rex MD, Martin RJ. Evaluation of blood ves-sels and edema in the airways of asthma patients: regulation withclarithromycin treatment. Chest 2001; 120: 416-22.
221. Johnston SL. Macrolide antibiotics and asthma treatment. J AllergyClin Immunol 2006; 117: 1233-6.
222. Shinkai M, Park CS, Rubin BK. Immunomodulatory effects ofmacrolide antibiotics. Clin Pulm Med 2005; 12: 341-8.
223. Caramori G, Papi A. Telithromycin in acute exacerbations ofasthma. N Engl J Med 2006; 355: 96; author reply 97-98.
224. Barnes PJ. Cytokine-directed therapies for the treatment of chronicairway diseases. Cytokine Growth Factor Rev 2003b; 14: 511-22.
225. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
226. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, ahumanized anti-human interleukin-5 antibody, in severe persistentasthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655-9.
227. Flood-Page P, Swenson C, Faiferman I, et al. International Mepoli-zumab Study Group. A study to evaluate safety and efficacy of me-polizumab in patients with moderate persistent asthma. Am JRespir Crit Care Med 2007; 176: 1062-71.
228. Büttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonalanti-interleukin-5 treatment suppresses eosinophil but not T-cellfunctions. Eur Respir J 2003; 21: 799-803.
229. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab andexacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
230. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab forprednisone-dependent asthma with sputum eosinophilia. N Engl JMed 2009; 360: 985-93.
231. Levine SJ, Wenzel SE. Narrative review: the role of Th2 immunepathway modulation in the treatment of severe asthma and its phe-notypes. Ann Intern Med 2010; 152: 232-7.
232. Rothenberg ME, Klion AD, Roufosse FE, et al. Mepolizumab HESStudy Group. Treatment of patients with the hypereosinophilicsyndrome with mepolizumab. N Engl J Med 2008; 358: 1215-1228.Erratum in: N Engl J Med 2008; 358: 2530.
233. Gao J, Shan G, Sun B, Thompson PJ, Gao X. Association betweenpolymorphism of tumour necrosis factor alpha-308 gene promoterand asthma: a meta-analysis. Thorax 2006; 61: 466-71.
234. Hersh CP, Demeo DL, Lange C, et al. Attempted replication ofreported chronic obstructive pulmonary disease candidate gene as-sociations. Am J Respir Cell Mol Biol 2005; 33: 71-8.
235. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role oftumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697-708.
236. Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W,Ermert L. In situ localization of TNFalpha/beta, TACE and TNFreceptors TNF-R1 and TNF-R2 in control and LPS-treated lung tis-sue. Cytokine 2003; 22: 89-100.
237. Thomas PS, Yates DH, Barnes PJ. TNF-alpha increases airwayresponsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152: 76-80.
238. Rennard SI, Fogarty C, Kelsen S, et al. COPD Investigators. Thesafety and efficacy of infliximab in moderate to severe chronic ob-structive pulmonary disease. Am J Respir Crit Care Med 2007;175: 926-34.
239. Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors inasthma and COPD: we must not throw the baby out with the bathwater. Pulm Pharmacol Ther 2010; 23: 121-8.
240. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL,Montori V. Anti-TNF antibody therapy in rheumatoid arthritis andthe risk of serious infections and malignancies: systematic reviewand meta-analysis of rare harmful effects in randomized controlledtrials. JAMA 2006; 295: 2275-2285. Erratum in: JAMA 2006; 295:2482.
241. Calabrese L. The yin and yang of tumor necrosis factor inhibitors. Cleve Clin J Med 2006; 73: 251-6.
242. Erzurum SC. Inhibition of tumor necrosis factor alpha for refrac-tory asthma. N Engl J Med 2006; 354: 754-8.
243. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor(TNFalpha) as a novel therapeutic target in symptomatic corticoste-roid dependent asthma. Thorax 2005; 60: 1012-8.
244. Townley RG, Horiba M. Airway hyperresponsiveness: a story ofmice and men and cytokines. Clin Rev Allergy Immunol 2003; 24:85-110.
245. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factoralpha in subjects with mild asthma. Thorax 2002; 57: 774-8.
246. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a mono-clonal antibody directed against tumor necrosis factor-alpha inasthma. Am J Respir Crit Care Med 2006; 174: 753-62.
247. Wenzel SE, Barnes PJ, Bleecker ER, et al. T03 Asthma Investiga-tors. A randomized, double-blind, placebo-controlled study of tu-mor necrosis factor-alpha blockade in severe persistent asthma. AmJ Respir Crit Care Med 2009; 179: 549-58.
248. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association betweenchronic obstructive pulmonary disease and systemic inflammation:a systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
249. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences ininterleukin-8 and tumor necrosis factor-alpha in induced sputumfrom patients with chronic obstructive pulmonary disease orasthma. Am J Respir Crit Care Med 1996; 153: 530-4.
250. Vernooy JH, Küçükaycan M, Jacobs JA, et al. Local and systemicinflammation in patients with chronic obstructive pulmonary dis-ease: soluble tumor necrosis factor receptors are increased in spu-tum. Am J Respir Crit Care Med 2002; 166: 1218-24.
251. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernandez N,Talamo C. keletal muscle inflammation and nitric oxide in patientswith COPD. Eur Respir J 2005; 26: 390-7.
252. Lewis MI. Apoptosis as a potential mechanism of muscle cachexiain chronic obstructive pulmonary disease. Am J Respir Crit CareMed 2002; 166: 434-6.
253. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumornecrosis factor-alpha drives 70% of cigarette smoke-induced em-physema in the mouse. Am J Respir Crit Care Med 2004; 170: 492-8.
254. Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severityof elastase-induced emphysema is decreased in tumor necrosis fac-tor-alpha and interleukin-1beta receptor-deficient mice. Lab Invest 2002; 82: 79-85.
255. Lundblad LK, Thompson-Figueroa J, Leclair T, et al. Tumor ne-crosis factor-alpha overexpression in lung disease: a single causebehind a complex phenotype. Am J Respir Crit Care Med 2005;171: 1363-70.
256. van der Vaart H, Koëter GH, Postma DS, Kauffman HF, tenHacken NH. First study of infliximab treatment in patients withchronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 465-469.
257. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the pre-vention of hospitalisation for chronic obstructive pulmonary dis-ease. Pulm Pharmacol Ther 2008; 21: 234-238.
258. Adcock IM, Caramori G, Chung KF. New targets for drug deve-lopment in asthma. Lancet 2008b; 372: 1073-1087.
259. Nevin BJ, Broadley KJ. Comparative effects of inhaled budesonideand the NO-donating budesonide derivative, NCX 1020, againstleukocyte influx and airway hyperreactivity following lipopolysac-charide challenge. Pulm Pharmacol Ther 2004; 17: 219-32.
260. Paul-Clark MJ, Roviezzo F, Flower RJ, et al. Glucocorticoid recep-tor nitration leads to enhanced anti-inflammatory effects of novelsteroid ligands. J Immunol 2003; 171: 3245-52.
261. Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory gluco-corticoid receptor ligand with reduced side effects exhibits an al-tered protein-protein interaction profile. Proc Natl Acad Sci USA 2007; 104: 19244-19249.
262. Ogawa S, Lozach J, Benner C, et al. Molecular determinants ofcrosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122: 707-721.
263. Farrow SN. Nuclear receptors: doubling up in the lung. Curr OpinPharmacol 2008; 8: 275-9.
264. Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphati-dylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 2007; 321: 1-8.
265. Rothschild BM. Review: individual DMARDs have similar effi-cacy for RA, but combination therapy improves response. Evid Based Med 2008; 13: 76.
266. Bodor N, Buchwald P. Corticosteroid design for the treatment ofasthma: structural insights and the therapeutic potential of soft cor-ticosteroids. Curr Pharm Des 2006; 12(25): 3241-60.
267. Hohenegger M. Novel and current treatment concepts using pul-monary drug delivery. Curr Pharm Des 2010; 16(22): 2484-92.
268. Miller-Larsson A, Selroos O. Advances in asthma and COPDtreatment: combination therapy with inhaled corticosteroids andlong-acting beta 2-agonists. Curr Pharm Des 2006; 12(25): 3261-79.